radial spoke head component 9Genealiases: C6orf206 · CILD12 · MRPS18AL1
Q-omics provides the consensus-scored RSPH9 profile across patient tissues and cancer cell-line models. RSPH9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RSPH9 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RSPH9 RNA expression shows 18,936 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRC, and ACC as cancer lineages where RSPH9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RSPH9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RSPH9 survival associations across molecular data types. RSPH9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RSPH9 RNA expression–survival associations across cancer types. High RSPH9 expression shows unfavorable associations in LGG, ESCA, LIHC, KICH and COAD, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RSPH9 RNA expression.
This table summarizes RSPH9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RSPH9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RSPH9 shows lower tumor expression in KICH, LUSC and LUAD and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher RSPH9 RNA expression in tumor versus normal tissue (log2 FC = +1.194, t-test p < 0.001).
This table shows molecular features associated with RSPH9 in patient tissues and cancer cell lines. In patient samples, RSPH9 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RSPH9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
